EGFR and prostate carcinoma: Moreover, pathway enrichment analysis demonstrated that these seven hub genes were enriched in Th17 cell differentiation, PD-L1 expression, and PD-1 checkpoint pathways in cancer, acute myeloid leukemia, pancreatic cancer, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor resistance, natural killer cell-mediated cytotoxicity, prostate cancer, T cell receptor signaling pathway, hypoxia inducible factor (HIF)-1 signaling, and phospholipase D signaling pathway (Figure 5D).